Terra Innovatum Srl, a developer of micro-modular nuclear reactors, and GSR III Acquisition Corp. , a publicly traded special purpose acquisition company, announced that it has accelerated its go-to-market plans for life-saving cancer isotope production with the SOLO micro-modular reactor.

Health Technology Insights: NextGen Healthcare Completes CEO Transition Ahead of Annual User Group Meeting

Terra Innovatum is developing collaborative business models and frameworks to engage with leading isotope producers and distributors such as NorthStar, ANSTO, BWXT Medical, IRE, NRG, NTP Radioisotopes, and Nordion to broaden access, strengthen partnerships, and expand global market reach.

A Micro Reactor with a Massive Impact on Global Healthcare

According to the World Nuclear Association, over 10,000 hospitals worldwide use radioisotopes in medicine with reports estimating that the nuclear radioisotope market will grow annually from $7 billion in 2025 to $11.68 billion by 2030.

Health Technology Insights: John D’Angelo Named CEO of Northwell Health

For decades, the global healthcare system has relied on a handful of large nuclear reactors to produce the medical isotopes essential for diagnostics, cancer therapies, and sterilization of medical equipment. This fragile, centralized model—plagued by aging infrastructure, costly logistics, and recurring shortages—has left patients waiting for critical scans and treatments.

Terra Innovatum’s SOLO microreactor is poised to change that. Compact, safe, and purpose-built for isotope production, SOLO enables localized, on-demand generation of radioisotopes—even in remote regions where conventional reactors and supply chains cannot reach.

“SOLO is not only an energy innovation, but also a healthcare breakthrough,” said Dr. Massimo Morichi, Chief Strategy Officer of Terra Innovatum, who brings four decades of experience developing advanced nuclear technologies worldwide. “By decentralizing isotope production, SOLO ensures hospitals and patients gain faster, more reliable access to the materials that modern medicine depends on.”

Why SOLO Matters

Medical isotopes are the invisible backbone of modern healthcare. Among the most vital are:

  • Molybdenum-99 (Mo-99)/Technetium-99m (Tc-99m): cornerstone of diagnostic imaging.
  • Iodine-131: essential for thyroid cancer treatment.
  • Cobalt-60: critical for radiotherapy and sterilization.
  • Iridium-192: supports brachytherapy.
  • Lutetium-177: key for precision radiotherapy.

Today, most of these isotopes come from a few centralized reactors—such as the High Flux Reactor in the Netherlands or Canada’s CANDU fleet—meaning outages or delays have worldwide consequences. While cyclotrons (large machines that produce radioisotopes) provide partial relief, their output remains limited and costly.

SOLO, currently advancing through U.S. NRC licensing and expected to be commercially available by 2028, provides a resilient, modular alternative.

A Microreactor Engineered for Isotopes

Unlike conventional reactors, SOLO is designed as a precision isotope factory:

  • Features dedicated irradiation channels for multi-target insertion.
  • Integrated hot cell connections for safe processing and extraction.
  • Capacity to produce multiple isotopes simultaneously.

A single SOLO can generate enough Tc-99m for thousands of diagnostic procedures annually, covering the needs of a small regional hospital. Expanded multi-target operation increases flexibility, redundancy, and scalability.

Beyond Diagnostics: On-Demand Cancer Therapy

SOLO’s flexible design supports both diagnostic and therapeutic isotope production, including:

  • Lutetium-177 for neuroendocrine and prostate cancer therapies.
  • Iodine-131 for thyroid cancer diagnostics and treatment.
  • Actinium-225 (Ac-225): an alpha-emitter for next-generation therapies.
  • Iridium-192 for brachytherapy.
  • Cobalt-60 for radiotherapy and sterilization.

This dual capability supports the emerging field of theranostics, where diagnosis and therapy are seamlessly integrated—revolutionizing cancer care.

A Global Game-Changer

With demand for isotopes rising worldwide, centralized supply is increasingly unsustainable. SOLO’s decentralized, portable, and multi-target approach allows deployment in hospitals, regional medical hubs, and even remote geographies across Africa, South America, Asia, and island nations.

By producing isotopes close to where they are needed, SOLO reduces delays, costs, and reliance on vulnerable supply chains. For patients, this translates into faster diagnoses, quicker treatment, and improved survival rates.

Health Technology Insights: Cynosure Lutronic Redefines Skin Resurfacing with the Launch of the eCO2 3D Laser

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source – GlobeNewswire